✦ LIBER ✦

Therapeutic benefit of blocking interleukin-6 activity with an anti–interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: A randomized, double-blind, placebo-controlled, dose-escalation trial

✍ Scribed by E. H. S. Choy; D. A. Isenberg; T. Garrood; S. Farrow; Y. Ioannou; H. Bird; N. Cheung; B. Williams; B. Hazleman; R. Price; K. Yoshizaki; N. Nishimoto; T. Kishimoto; G. S. Panayi

Publisher: John Wiley and Sons
Year: 2002
Tongue: English
Weight: 176 KB
Volume: 46
Category: Article
ISSN: 0004-3591
DOI: 10.1002/art.10623

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Treatment of rheumatoid arthritis with h

Treatment of rheumatoid arthritis with humanized anti–interleukin-6 receptor antibody: A multicenter, double-blind, placebo-controlled trial

✍ Norihiro Nishimoto; Kazuyuki Yoshizaki; Nobuyuki Miyasaka; Kazuhiko Yamamoto; Sh 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 163 KB 👁 2 views

## Abstract ## Objective Interleukin‐6 (IL‐6) is a pleiotropic cytokine that regulates the immune response, inflammation, and hematopoiesis. Overproduction of IL‐6 plays pathologic roles in rheumatoid arthritis (RA), and the blockade of IL‐6 may be therapeutically effective for the disease. This s

Anti–interleukin-6 receptor antibody the

Anti–interleukin-6 receptor antibody therapy favors adrenal androgen secretion in patients with rheumatoid arthritis: A randomized, double-blind, placebo-controlled study

✍ Rainer H. Straub; Peter Härle; Seizo Yamana; Takemasa Matsuda; Kiyoshi Takasugi; 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 219 KB 👁 2 views

LY2439821, a humanized anti–interleukin-

LY2439821, a humanized anti–interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I randomized, double-blind, placebo-controlled, proof-of-concept study

✍ M. C. Genovese; F. Van den Bosch; S. A. Roberson; S. Bojin; I. M. Biagini; Peter 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 182 KB

Double-blind randomized controlled clini

Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate

✍ R. N. Maini; P. C. Taylor; J. Szechinski; K. Pavelka; J. Bröll; G. Balint; P. Em 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 320 KB 👁 2 views

Rapid and sustained improvement in bone

Rapid and sustained improvement in bone and cartilage turnover markers with the anti–interleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate: Results from a substudy of the multicenter double-blind, placebo-controlled trial of tocilizumab in inadequate responders to methotrexate alone

✍ Patrick Garnero; Elizabeth Thompson; Thasia Woodworth; Josef S. Smolen 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 276 KB 👁 2 views

## Abstract ## Objective To investigate the effects of tocilizumab (TCZ) added to a stable dosage of methotrexate (MTX) on biochemical markers of bone and cartilage metabolism in patients in the multicenter double‐blind, placebo‐controlled OPTION (Tocilizumab Pivotal Trial in Methotrexate Inadequa